Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies - PubMed
Koné Kaniga 1 ,
Article ImagesWorldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies
Koné Kaniga et al. Antimicrob Agents Chemother. 2010 May.
Abstract
The worldwide increase in fluoroquinolone-resistant and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae pathogens has led to doripenem and other carbapenems assuming a greater role in the treatment of serious infections. We analyzed data from 6 phase 3 multinational doripenem clinical trials on ciprofloxacin-resistant Enterobacteriaceae isolates consisting of all genera (CIPRE) and ESBL-producing Enterobacteriaceae isolates consisting of Escherichia coli, Klebsiella spp., and Proteus spp. with ceftazidime MICs of >or=2 microg/ml (ESBLE) for prevalence by geographic region and disease type, in vitro activities of doripenem and comparator agents, and clinical or microbiologic outcomes in doripenem- and comparator-treated patients across disease types (complicated intra-abdominal infection [cIAI], complicated urinary tract infection [cUTI], and nosocomial pneumonia [NP]). Of 1,830 baseline Enterobacteriaceae isolates, 88 (4.8%) were ESBLE and 238 (13.0%) were CIPRE. The incidence of ESBLE was greatest in Europe (7.8%); that of CIPRE was higher in South America (15.9%) and Europe (14.4%). ESBLE incidence was highest in NP (12.9%) cases; that of CIPRE was higher in cUTI (18.3%) and NP (14.9%) cases. Against ESBLE and CIPRE, carbapenems appeared more active than other antibiotic classes. Among carbapenems, doripenem and meropenem were most potent. Doripenem had low MIC(90)s for CIPRE (0.5 microg/ml) and ESBLE (0.25 microg/ml). Doripenem and comparators were highly clinically effective in infections caused by Enterobacteriaceae, irrespective of their ESBL statuses. The overall cure rates were the same for doripenem (82%; 564/685) and the comparators (82%; 535/652) and similar for ESBLE (73% [16/22] versus 72% [21/29]) and CIPRE (68% [47/69] versus 52% [33/64]). These findings indicate that doripenem is an important therapeutic option for treating serious infections caused by ESBLE and CIPRE.
Trial registration: ClinicalTrials.gov NCT00210938 NCT00210990 NCT00211003 NCT00211016 NCT00229021 NCT00229060.
Figures
Similar articles
-
Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS. Mendes RE, et al. Diagn Microbiol Infect Dis. 2009 Apr;63(4):415-25. doi: 10.1016/j.diagmicrobio.2009.02.002. Epub 2009 Feb 26. Diagn Microbiol Infect Dis. 2009. PMID: 19249175
-
Betriu C, Gómez M, López-Fabal F, Culebras E, Rodríguez-Avial I, Picazo JJ. Betriu C, et al. Eur J Clin Microbiol Infect Dis. 2010 Sep;29(9):1179-81. doi: 10.1007/s10096-010-0974-3. Epub 2010 Jun 4. Eur J Clin Microbiol Infect Dis. 2010. PMID: 20521156
-
[Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
Eser OK, Altun Uludağ H, Ergin A, Boral B, Sener B, Hasçelik G. Eser OK, et al. Mikrobiyol Bul. 2014 Jan;48(1):59-69. Mikrobiyol Bul. 2014. PMID: 24506716 Turkish.
-
Peterson LR. Peterson LR. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:181-4. doi: 10.1111/j.1469-0691.2007.01864.x. Clin Microbiol Infect. 2008. PMID: 18154544 Review.
-
Sheu CC, Lin SY, Chang YT, Lee CY, Chen YH, Hsueh PR. Sheu CC, et al. Expert Rev Anti Infect Ther. 2018 Mar;16(3):205-218. doi: 10.1080/14787210.2018.1436966. Epub 2018 Feb 9. Expert Rev Anti Infect Ther. 2018. PMID: 29402125 Review.
Cited by
-
Nicolas-Chanoine MH, Vigan M, Laouénan C, Robert J; “E-carb Study Group”. Nicolas-Chanoine MH, et al. Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):383-393. doi: 10.1007/s10096-018-3438-9. Epub 2018 Nov 28. Eur J Clin Microbiol Infect Dis. 2019. PMID: 30488368
-
Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Rodríguez-Baño J, et al. Clin Microbiol Rev. 2018 Feb 14;31(2):e00079-17. doi: 10.1128/CMR.00079-17. Print 2018 Apr. Clin Microbiol Rev. 2018. PMID: 29444952 Free PMC article. Review.
-
Molecular Characteristics of Carbapenem-Resistant Enterobacter cloacae in Ningxia Province, China.
Shi Z, Zhao H, Li G, Jia W. Shi Z, et al. Front Microbiol. 2017 Jan 31;8:94. doi: 10.3389/fmicb.2017.00094. eCollection 2017. Front Microbiol. 2017. PMID: 28197140 Free PMC article.
-
Lee HJ, Choi JK, Cho SY, Kim SH, Park SH, Choi SM, Lee DG, Choi JH, Yoo JH. Lee HJ, et al. Infect Chemother. 2016 Sep;48(3):166-173. doi: 10.3947/ic.2016.48.3.166. Epub 2016 Sep 8. Infect Chemother. 2016. PMID: 27659436 Free PMC article.
-
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Kalil AC, et al. Clin Infect Dis. 2016 Sep 1;63(5):e61-e111. doi: 10.1093/cid/ciw353. Epub 2016 Jul 14. Clin Infect Dis. 2016. PMID: 27418577 Free PMC article.
References
-
- Chastre, J., R. Wunderink, P. Prokocimer, M. Lee, K. Kaniga, and I. Friedland. 2008. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med. 36:1089-1096. - PubMed
-
- Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement, 19087-1898. Clinical and Laboratory Standards Institute, Wayne, PA.
-
- Kattan, J. N., M. V. Villegas, and J. P. Quinn. 2008. New developments in carbapenems. Clin. Microbiol. Infect. 14:1102-1111. - PubMed
-
- Keam, S. J. 2008. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 68:2021-2057. - PubMed
-
- Lucasti, C., A. Jasovich, O. Umeh, J. Jiang, K. Kaniga, and I. Friedland. 2008. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin. Ther. 30:868-883. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous